Skip to content

Depreciation at other companies

Stryker logo
StrykerSYK
$120M+14.3%
LivaNova logo
LivaNovaLIVN
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY

Other financials

Income statement

See full
Revenue$22.1M-2.0%
Gross profit$18.0M+4.1%
Operating income-$5.6M-8.2%
Net income-$6.7M-1.5%
EPS (diluted)-$0.20+4.8%

Balance sheet

See full
Cash & equivalents$15.6M-42.4%
Total debt$70.5M-3.7%
Total equity$14.5M-40.4%
Total assets$98.9M-10.3%

Cash flow

See full
Operating cash flow-$5.9M+21.1%
CapEx$117.0K+216%
Free cash flow-$6.0M+20.0%

Valuation

See full
Market cap$557.77M+63.4%
Enterprise value$612.6M+58.1%
P/S5.6×+1.6×

Profitability

See full
Gross margin78.3%+3.5pp
Operating margin-16.8%-3.5pp
Net margin-21.7%-4.5pp
FCF margin-10.3%-3.5pp

Returns & leverage

See full
Return on equity-111.4%-13.1pp
Debt / equity4.9×+1.9×
Current ratio5.4×-1.2×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuropace, Inc.'s depreciation?
Neuropace, Inc. (NPCE) reported depreciation of $60K in Q1 2026.
How has Neuropace, Inc.'s depreciation changed year-over-year?
Neuropace, Inc.'s depreciation increased by 22.4% year-over-year, from $49K to $60K.
What is the long-term trend for Neuropace, Inc.'s depreciation?
Over 4 years (2021 to 2025), Neuropace, Inc.'s depreciation has grown at a -1.7% compound annual growth rate (CAGR), from $353K to $329K.